Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Zimmer

Showing results (31-40 of 218) with videos related to

Pageof 22
Sort By:
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 5, 2016
Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanomaKatharina C Kähler, Jessica C Hassel, Lucie Heinzerling, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 11, 2020
Katharina C Kähler, Jessica C Hassel, Lucie Heinzerling, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 4, 2020
Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an updateKatharina C Kähler, Jessica C Hassel, Lucie Heinzerling, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2013
Combination of BRAF Inhibitors and Brain Radiotherapy in Patients With Metastatic Melanoma Shows Minimal Acute ToxicityNatalia Rompoti, Bastian Schilling, Elisabeth Livingstone, et al.
Gut|December 17, 2017
Sebaceous tumours: more than skin deepFinja Jockenhöfer, Tobias T Schimming, Jörg Schaller, et al.
Cancer Medicine|December 22, 2017
Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanomaJessica C Hassel, Kristina Buder-Bakhaya, Carolin Bender, et al.
Frontiers in Immunology|May 29, 2024
Case report: Durable complete response of a mucosal melanoma of the rectum after neoadjuvant immunotherapy with ipilimumab plus nivolumabOskar Krueger, Robin Eisenburger, Alpaslan Tasdogan, et al.
European Journal of Cancer (Oxford, England : 1990)|March 29, 2026
Diagnostic and prognostic parameters for immune checkpoint inhibitor-related myocarditis: A meta-analysisTobias Lerchner, Florian Buehning, Julia Vogel, et al.
European Journal of Cancer (Oxford, England : 1990)|September 4, 2020
Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter studyMartin Salzmann, Ulrike Leiter, Carmen Loquai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2013
Incidence of new primary melanomas after diagnosis of stage III and IV melanomaLisa Zimmer, Lauren E Haydu, Alexander M Menzies, et al.
Pageof 22

Showing results (31-40 of 218) with videos related to

Sort By:
Pageof 22
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 5, 2016
Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanomaKatharina C Kähler, Jessica C Hassel, Lucie Heinzerling, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 11, 2020
Katharina C Kähler, Jessica C Hassel, Lucie Heinzerling, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 4, 2020
Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an updateKatharina C Kähler, Jessica C Hassel, Lucie Heinzerling, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2013
Combination of BRAF Inhibitors and Brain Radiotherapy in Patients With Metastatic Melanoma Shows Minimal Acute ToxicityNatalia Rompoti, Bastian Schilling, Elisabeth Livingstone, et al.
Gut|December 17, 2017
Sebaceous tumours: more than skin deepFinja Jockenhöfer, Tobias T Schimming, Jörg Schaller, et al.
Cancer Medicine|December 22, 2017
Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanomaJessica C Hassel, Kristina Buder-Bakhaya, Carolin Bender, et al.
Frontiers in Immunology|May 29, 2024
Case report: Durable complete response of a mucosal melanoma of the rectum after neoadjuvant immunotherapy with ipilimumab plus nivolumabOskar Krueger, Robin Eisenburger, Alpaslan Tasdogan, et al.
European Journal of Cancer (Oxford, England : 1990)|March 29, 2026
Diagnostic and prognostic parameters for immune checkpoint inhibitor-related myocarditis: A meta-analysisTobias Lerchner, Florian Buehning, Julia Vogel, et al.
European Journal of Cancer (Oxford, England : 1990)|September 4, 2020
Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter studyMartin Salzmann, Ulrike Leiter, Carmen Loquai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2013
Incidence of new primary melanomas after diagnosis of stage III and IV melanomaLisa Zimmer, Lauren E Haydu, Alexander M Menzies, et al.
Pageof 22